Joined September 2017
- Tweets 21
- Following 25
- Followers 2
- Likes 124
4 Photos and videos
Toshifumi Hoki retweeted
19 Jan 2023
🔥Excellent news: Pivotal phase III IMbrave050 study is positive: The first positive adjuvant trial in #HCC🔥
👉Atezolizumab Avastin improves RFS in pts at high risk of recurrence following surgery
@myESMO @OncoAlert @EASLedu #livertwitter
68
162
18,813
Toshifumi Hoki retweeted
27 Jul 2021
I'd like to thank DOD Lung Cancer Research Program for supporting our research. I had a great pleasure working at VA hosp as a resident and staff surgeon before. I hope our work will help improve care for veterans. @wwp @VeteransHealth
cdmrp.army.mil/lcrp/research…
1
2
「森友」文書不開示は違法。
国が記録を意図的に不開示にした上で、廃棄を進める違法行為があったとして３３万円の賠償を大阪高裁が命じた。
国民として誰でも訴訟出来るので、同じ訴状を近くの裁判所に出すと誰でも33万円貰えるって事だよね？
新たな給付金。
news.yahoo.co.jp/articles/8d…
81
444
2,978
Toshifumi Hoki retweeted
8 Jun 2021
本会議終了後、視察で渋谷へ。LUUP乗ってきた！公道でノーヘルですが何か？ヒャッハー！
電動シェアキックボード事故も報道される中で、事業社さんの苦労も聞きつつ、主意書作成中です。百聞は”一験”に如かずですね。会期末までに質問主意書仕上げて政府に出します。
107
223
2,265
Toshifumi Hoki retweeted
8 Jun 2021
2 Jun 2021
New #JITC article: In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models @lab_ito @KunleOdunsiMD ow.ly/J91I50F0wrq
1
4
Toshifumi Hoki retweeted
2 Jun 2021
New #JITC article: In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models @lab_ito @KunleOdunsiMD ow.ly/J91I50F0wrq
1
6
11
Toshifumi Hoki retweeted
29 May 2021
Glad to share our work on the mechanism underlying the generation of tumor-specific #CD8 #Tcells by #neoantigen #vaccination, and the utility of #CX3CR1 as a circulating #biomarker.
#CD40, #CD80, #CD86, #cDC1
rdcu.be/clyQ1
5
6
17 Sep 2020
IFNγ signaling paves the way for effective checkpoint blockade acir.org/weekly-digests/2020…
Toshifumi Hoki retweeted
17 Sep 2020
Any role of #cDC1s in adoptive #Immunotherapy? Glad to see our new paper @J_Immunol. A BIG thank you to everyone involved @RoswellPark and awesome collaborators. dx.doi.org/10.4049/jimmunol.…
3
3
SPOTLIGHT: CX3CR1-CD8 T cells are critical in antitumor efficacy, but functionally suppressed in the tumor microenvironment @RoswellPark Originally published in @JCI_insight To read our summary click bit.ly/3avRKQB and scroll all the way down.
3
3
Toshifumi Hoki retweeted
17 Aug 2020
Very nice to see our paper published in JCI insight. Congrats on Drs. Yamauchi, Hoki and Oba. I appreciated help by awesome collaborators.
4 May 2020
CX3CR1–CD8 T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment buff.ly/2KXuVel @RoswellPark #Immunology
1
2
Toshifumi Hoki retweeted
24 Jun 2020
Dr. Fumito Ito will share results today of a clinical trial assessing a biomarker as a way to predict response to therapies that target the checkpoint protein PD-1. Dr. Ito's online session takes place at 9:20am EDT. #AACR20 roswellpark.org/newsroom/202…
4
7
Toshifumi Hoki retweeted
6 Jul 2020
こんにちは！
この度、投資初心者向けセミナーで講演することになりましたー☺️
日時 8月8日（土）14時
場所 ワテラスコモンホール（お茶の水駅近く）
定員 50名
参加費 無料
※詳細はURLからご確認ください
定員の数に限りがあって申し訳ないです🙇♂️
#じょにぃちゃんねる
sunward-t.co.jp/seminar/2020…
2
3
19